Corient IA LLC Invests $508,000 in Koninklijke Philips N.V. $PHG

Key Points

• Corient IA LLC has invested approximately $508,000 in Koninklijke Philips N.V. by purchasing 20,000 shares during the first quarter.
• Multiple institutional investors have significantly increased their holdings in Koninklijke Philips, with Colonial Trust Co SC raising its position by 724.0% during the fourth quarter.
• The company reported an EPS of $0.41 for its last quarter, exceeding analysts' expectations of $0.29, with revenues hitting $5.05 billion.

Corient IA LLC bought a new stake in Koninklijke Philips N.V. (NYSE:PHG - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 20,000 shares of the technology company's stock, valued at approximately $508,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Colonial Trust Co SC raised its position in shares of Koninklijke Philips by 724.0% in the fourth quarter. Colonial Trust Co SC now owns 1,409 shares of the technology company's stock valued at $36,000 after purchasing an additional 1,238 shares during the period. Bessemer Group Inc. raised its position in shares of Koninklijke Philips by 2,935.4% in the first quarter. Bessemer Group Inc. now owns 1,973 shares of the technology company's stock valued at $51,000 after purchasing an additional 1,908 shares during the period. Caitong International Asset Management Co. Ltd raised its position in shares of Koninklijke Philips by 1,170.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,439 shares of the technology company's stock valued at $62,000 after purchasing an additional 2,247 shares during the period. Castlekeep Investment Advisors LLC bought a new stake in shares of Koninklijke Philips in the fourth quarter valued at approximately $114,000. Finally, Allworth Financial LP raised its position in shares of Koninklijke Philips by 16.2% in the first quarter. Allworth Financial LP now owns 4,638 shares of the technology company's stock valued at $115,000 after purchasing an additional 645 shares during the period. Institutional investors own 13.67% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen lowered shares of Koninklijke Philips from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Koninklijke Philips currently has an average rating of "Buy".

Koninklijke Philips Price Performance

Koninklijke Philips stock traded up $0.8960 during midday trading on Friday, reaching $28.3360. 340,541 shares of the stock were exchanged, compared to its average volume of 991,275. The company's fifty day moving average is $25.11 and its 200-day moving average is $25.02. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.81 and a current ratio of 1.26. The firm has a market cap of $27.29 billion, a PE ratio of 149.18, a PEG ratio of 0.75 and a beta of 0.75. Koninklijke Philips N.V. has a 52 week low of $21.48 and a 52 week high of $32.91.

Koninklijke Philips (NYSE:PHG - Get Free Report) last announced its earnings results on Tuesday, July 29th. The technology company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.12. Koninklijke Philips had a net margin of 1.00% and a return on equity of 11.95%. The company had revenue of $5.05 billion during the quarter, compared to analyst estimates of $4.35 billion. On average, sell-side analysts forecast that Koninklijke Philips N.V. will post 1.63 EPS for the current year.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.